KalVista Pharmaceuticals Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Los beneficios de KalVista Pharmaceuticals han disminuido a una tasa media anual de -33.9%, mientras que en la industria Biotechs los beneficios crecieron en un 17.7% anualmente. Los ingresos han ido disminuyendo a una tasa media de 76% al año.

Información clave

-33.9%

Tasa de crecimiento de los beneficios

-20.6%

Tasa de crecimiento del BPA

Crecimiento de la industria Biotechs	-14.6%
Tasa de crecimiento de los ingresos	-76.0%
Rentabilidad financiera	-122.3%
Margen neto	n/a
Última actualización de beneficios	31 Jan 2024

Actualizaciones de resultados anteriores recientes

Recent updates

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero KalVista Pharmaceuticals. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

DB:4XC1 Ingresos, gastos y beneficios (USD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A
31 Jan 24	0	-108	39
31 Oct 23	0	-101	35
31 Jul 23	0	-95	32
30 Apr 23	0	-93	31
31 Jan 23	0	-91	30
31 Oct 22	0	-92	30
31 Jul 22	0	-89	29
30 Apr 22	0	-82	26
31 Jan 22	0	-73	25
31 Oct 21	0	-61	22
31 Jul 21	0	-52	19
30 Apr 21	0	-46	17
31 Jan 21	4	-38	14
31 Oct 20	5	-37	13
31 Jul 20	9	-33	13
30 Apr 20	13	-29	13
31 Jan 20	12	-31	13
31 Oct 19	14	-26	13
31 Jul 19	16	-23	12
30 Apr 19	16	-21	11
31 Jan 19	18	-13	10
31 Oct 18	16	-14	9
31 Jul 18	12	-16	9
30 Apr 18	8	-16	9
31 Jan 18	4	-19	3
31 Oct 17	2	-22	6
31 Jul 17	1	-21	4
30 Apr 17	2	-21	11
31 Jan 17	2	-23	10
31 Oct 16	2	-18	6
31 Jul 16	2	-18	5
30 Apr 16	2	-15	3
30 Apr 15	2	-9	2

Ingresos de calidad: 4XC1 actualmente no es rentable.

Margen de beneficios creciente: 4XC1 actualmente no es rentable.

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: 4XC1 no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 33.9% al año.

Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de 4XC1 en el último año con su promedio de 5 años, ya que actualmente no es rentable.

Beneficios vs. Industria: 4XC1 no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Biotechs (-14.4%).

Rentabilidad financiera

Alta ROE: 4XC1 tiene una rentabilidad financiera negativa (-122.26%), ya que actualmente no es rentable.

KalVista Pharmaceuticals Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Información clave

Actualizaciones de resultados anteriores recientes

First quarter earnings released

Recent updates

Forecast to breakeven in 2027

Kalvista Pharmaceuticals, Inc. Appoints William C. Fairey to the Board of Directors

KalVista Pharmaceuticals, Inc. to Present HAE Attack Journey Data at 2024 HAEi Regional Conference Americas

KalVista Pharmaceuticals, Inc. Announces Board Changes

KalVista Pharmaceuticals, Inc. Receives UK Innovation Passport for Sebetralstat from UK Medicines and Healthcare Products Regulatory Agency

KalVista Pharmaceuticals, Inc. Receives UK Innovation Passport for Sebetralstat from UK Medicines and Healthcare Products Regulatory Agency

CEO & Director recently sold €817k worth of stock

KalVista Pharmaceuticals to Present Phase 3 Sebetralstat Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting

KalVista Pharmaceuticals, Inc. has filed a Follow-on Equity Offering.

New major risk - Share price stability

Kalvista Pharmaceuticals, Inc. Reports Phase 3 Konfident Trial Meets All Endpoints for Sebetralstat as First Oral On-Demand Therapy for Hereditary Angioedema

New minor risk - Profitability

New major risk - Financial position

Kalvista Pharmaceuticals Announces Phase 3 Konfident Trial Milestone Achieved

KalVista Pharmaceuticals to Present Data at the 2023 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology

KalVista Pharmaceuticals, Inc., Annual General Meeting, Sep 26, 2023

KalVista Pharmaceuticals, Inc. Appoints Nicole Sweeny as Chief Commercial Officer

KalVista Pharmaceuticals, Inc. Presents New Data at 2023 Meeting of the European Academy of Allergy and Clinical Immunology

KalVista Pharmaceuticals, Inc. Presents Data At 13Th C1-Inhibitor Deficiency & Angioedema Workshop

KalVista Pharmaceuticals, Inc. Provides Progress Updates on Sebetralstat Development

Kalvista Pharmaceuticals Announces Publication of Sebetralstat Phase 2 Data in the Lancet

Kalvista Pharmaceuticals Announces Benjamin L. Palleiko Promoted to President

KalVista Pharmaceuticals Presents Patient-Focused Data at American College of Allergy, Asthma & Immunology (ACAAI) 2022 Meeting

Kalvista Pharmaceuticals Announces Positive Phase 1 Data for Orally Disintegrating Tablet Formulation of Sebetralstat for Use in Hereditary Angioedema

KalVista Pharmaceuticals, Inc. Announces Management Changes

KalVista Pharmaceuticals, Inc. Presents New Patient-Centric Data at 2022 HAEi Global Leadership Workshop

KalVista Pharmaceuticals Announces Termination of KVD824 Phase 2 KOMPLETE Trial for Prophylactic Treatment of Hereditary Angioedema

Kalvista Pharmaceuticals, Inc. Announces Initiation of KONFIDENT-S Open Label Extension Study for Sebetralstat in Hereditary Angioedema

KalVista Pharmaceuticals, Inc., Annual General Meeting, Oct 13, 2022

No longer forecast to breakeven

KalVista Pharmaceuticals, Inc. Announces Board Changes

KalVista Pharmaceuticals, Inc. Presents Data Showing Rapid Reduction of Plasma Kallikrein Activity After Oral KVD900 Treatment and Early Symptom Relief from HAE Attacks in Patients

KalVista Pharmaceuticals, Inc. to Present Data on Oral On-Demand HAE Therapy KVD900 at AAAAI 2022

U.S. Food and Drug Administration Lifts the Clinical Hold on Kalvista Pharmaceuticals, Inc.’s Phase 2 Clinical Trial of KVD824 for Oral Prophylactic Treatment of Hereditary Angioedema

KalVista Pharmaceuticals, Inc. Provides Progress Update on Phase 2 Clinical Trial of KVD824 for Oral Prophylactic Treatment of Hereditary Angioedema

KalVista Pharmaceuticals Presents Data Showing Single On-Demand Treatment with Orally Administered KVD900 Significantly Slows Progression and Accelerates Resolution of Attacks in Patients with HAE

KalVista Pharmaceuticals, Inc.(NasdaqGM:KALV) dropped from Russell 3000E Value Index

KalVista Pharmaceuticals Presents Phase 2 Clinical Data of Oral KVD900 for Treatment of HAE at C1-Inhibitor Deficiency & Angioedema Workshop

KalVista Pharmaceuticals, Inc. Appoints Nancy Stuart to Board of Directors and Audit Committee

Revenue misses expectations

KalVista Pharmaceuticals Reports Positive Results for KVD900 Phase 2 Demonstrating Statistically and Clinically Significant Responses Across All Endpoints as an Oral On-Demand Treatment for HAE Attacks

New 90-day low: €12.50

Kalvista Pharmaceuticals, Inc. Provides Data on Kvd824 as Twice-Daily Oral Candidate for Prophylactic Treatment of Hae; Announces Novel Oral Factor Xiia Inhibitor Program as the Next Area of Development Focus

Revenue misses expectations

Kalvista Pharmaceuticals, Inc. Reports Demise of Arnold Oronsky on November 21, 2020

New 90-day high: €16.20

KalVista Pharmaceuticals, Inc. Announces Updated Guidance on the Data Release of Its Phase 2 Clinical Trial

New 90-day high: €14.60

KalVista Pharmaceuticals Provides Update on Oral Hereditary Angioedema Franchise

New 90-day high: €11.90

New 90-day high - €11.60

First quarter earnings released

New 90-day high - €11.50

New 90-day low - €8.55

Desglose de ingresos y gastosBeta

Historial de beneficios e ingresos

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Rentabilidad financiera

Rentabilidad económica

Rendimiento del capital invertido

Descubre empresas con buenos resultados en el pasado

Desglose de ingresos y gastos
Beta